{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,530M vs. cons $1,503M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Opzelura (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$295M vs. cons $309M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "EPS non-GAAP operating (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.30 vs. cons $2.25",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total Revenue FY 2026 (FY)",
      "prediction": "LOWER",
      "answer": "guide ~$5.5B mid vs. cons $5.75B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Opzelura FY 2026 (FY)",
      "prediction": "LOWER",
      "answer": "guide ~$825M mid vs. cons $895M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "EPS FY 2026 (FY)",
      "prediction": "BETTER",
      "answer": "guide ~$5.90 mid vs. cons $5.44",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -8.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -10.0,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 sell-side cuts H2 revenue estimates post-guide; EPS raise limits downside but does not flip the sign",
  "day5_confidence": "MEDIUM"
}